Bio-Techne, a provider of diagnostic tools and bioactive reagents, has signed an agreement with Thermo Fisher Scientific for the distribution of the former’s products in Europe.
The distribution deal will cover Bio-Techne’s portfolio of products such as antibodies, proteins, immunoassay kits, reagents, and enzymes to reach European laboratories and research institutions.
Thermo Fisher Scientific, which provides laboratory products and services, will use the European division of its Fisher Scientific Channel for this purpose.
Thermo Fisher Scientific Europe research and safety market president Claire Wallace said: “We are thrilled to forge this partnership with Bio-Techne, a company renowned for its pioneering advancements in the life sciences industry.
“By adding Bio-Techne’s high-quality products to our comprehensive portfolio, we aim to further empower scientists and researchers with the tools they need to drive breakthrough discoveries and advancements in healthcare.”
Bio-Techne’s offerings aim to expedite research and enhance results across various fields like cell and gene therapy, immunology, neuroscience, and others.
Bio-Techne president and CEO Kim Kelderman said: “We are excited to partner with Thermo Fisher to expand the reach of our products and services throughout Europe.
“By leveraging the Fisher Scientific Channel’s extensive European distribution network and industry expertise, we aim to enhance support for researchers and accelerate scientific discoveries that address some of the most pressing challenges in healthcare today.”
Last month, the diagnostic tools provider received the European In Vitro Diagnostic Regulation (IVDR) certification for its QuantideX qPCR BCR-ABL IS test kit to monitor chronic myeloid leukaemia. The in vitro diagnostic test, based on qPCR, measures BCR-ABL1 and ABL1 transcripts in blood samples from patients with CML to assess their reaction to tyrosine kinase inhibitor (TKI) therapy.
Listed on Nasdaq, Bio-Techne has a global workforce of over 3,000 and had recorded net sales of more than $1.1bn in 2023.
